Parkinson's disease: biomarkers, treatment, and risk factors
FN Emamzadeh, A Surguchov - Frontiers in neuroscience, 2018 - frontiersin.org
Parkinson's disease (PD) is a progressive neurodegenerative disorder caused mainly by
lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement …
lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement …
EFNS/MDS‐ES recommendations for the diagnosis of P arkinson's disease
A Berardelli, GK Wenning, A Antonini… - European journal of …, 2013 - Wiley Online Library
Background A Task Force was convened by the EFNS/MDS‐ES Scientist Panel on P
arkinson's disease (PD) and other movement disorders to systemically review relevant …
arkinson's disease (PD) and other movement disorders to systemically review relevant …
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
Purpose This joint practice guideline or procedure standard was developed collaboratively
by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear …
by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear …
[HTML][HTML] Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis
Many theories of cognitive aging are based on evidence that dopamine (DA) declines with
age. Here, we performed a systematic meta-analysis of cross-sectional positron emission …
age. Here, we performed a systematic meta-analysis of cross-sectional positron emission …
Biomarkers in Parkinson's disease
A Surguchov - … diseases biomarkers: Towards translating research to …, 2022 - Springer
Parkinson's disease (PD) is the second most common neurodegenerative disorder, with a
documented significant increase in its prevalence in the past three decades. Both …
documented significant increase in its prevalence in the past three decades. Both …
Recent advances in biomarkers for Parkinson's disease
R He, X Yan, J Guo, Q Xu, B Tang… - Frontiers in aging …, 2018 - frontiersin.org
Parkinson's disease (PD) is one of the common progressive neurodegenerative disorders
with several motor and non-motor symptoms. Most of the motor symptoms may appear at a …
with several motor and non-motor symptoms. Most of the motor symptoms may appear at a …
Gait speed in Parkinson disease correlates with cholinergic degeneration
Objective: We investigated dopaminergic and cholinergic correlates of gait speed in
Parkinson disease (PD) and non-PD control subjects to test the hypothesis that gait …
Parkinson disease (PD) and non-PD control subjects to test the hypothesis that gait …
Influences of dopaminergic system dysfunction on late-life depression
Deficits in cognition, reward processing, and motor function are clinical features relevant to
both aging and depression. Individuals with late-life depression often show impairment …
both aging and depression. Individuals with late-life depression often show impairment …
Novel focused ultrasound gene therapy approach noninvasively restores dopaminergic neuron function in a rat Parkinson's disease model
Therapies capable of decelerating, or perhaps even halting, neurodegeneration in
Parkinson's disease (PD) remain elusive. Clinical trials of PD gene therapy testing the …
Parkinson's disease (PD) remain elusive. Clinical trials of PD gene therapy testing the …
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease
DS Goldstein, P Sullivan, C Holmes… - Journal of …, 2013 - Wiley Online Library
Intra‐neuronal metabolism of dopamine (DA) begins with production of 3, 4‐
dihydroxyphenylacetaldehyde (DOPAL), which is toxic. According to the 'catecholaldehyde …
dihydroxyphenylacetaldehyde (DOPAL), which is toxic. According to the 'catecholaldehyde …